Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from FOXO Technologies ( (FOXO) ).
On February 6, 2026, FOXO Technologies Inc. disclosed that it had entered into a Series E Preferred Stock Exchange Agreement with Rennova Health Inc., effective December 31, 2025, to convert $200,000 in short-term advances made between December 4 and December 10, 2025 into equity. Under the deal, FOXO will issue 8,000 shares of its Series E Cumulative Redeemable Secured Preferred Stock, valued at $25 per share, to Rennova in full satisfaction of the prior advances, eliminating Rennova’s creditor status for that debt and removing a corresponding liability from FOXO’s balance sheet. The transaction, classified as a related-party deal because CEO Seamus Lagan controls both companies, was reviewed and approved solely by disinterested directors, who determined after heightened scrutiny that the terms were fair and in the best interests of FOXO and its unaffiliated shareholders; the private issuance relies on an exemption from Securities Act registration and is directed to Rennova as an accredited investor acquiring the securities for investment purposes.
The most recent analyst rating on (FOXO) stock is a Hold with a $0.01 price target. To see the full list of analyst forecasts on FOXO Technologies stock, see the FOXO Stock Forecast page.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Neutral.
The score is primarily held back by persistent losses and continued operating/free-cash-flow burn despite improving revenue and gross margin trends. Corporate events add mixed impact (operational progress but higher dilution risk), while valuation remains constrained by negative earnings and technicals cannot be substantiated from the missing indicator set.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc., a Delaware-based public company quoted on the OTC Markets, operates in the broader health and life sciences space and is subject to U.S. Securities Exchange Act reporting requirements. The company utilizes preferred equity instruments, such as its Series E Cumulative Redeemable Secured Preferred Stock, as part of its capital structure and financing strategy, reflecting an ongoing need for capital and active balance sheet management.
Technical Sentiment Signal: Sell
Current Market Cap: $306.3K
For a thorough assessment of FOXO stock, go to TipRanks’ Stock Analysis page.